- Epidemiology
- Variants
- Therapeutics
- Pediatric Vaccines
- Booster Shots
Epidemiology

Variants

Therapeutics

Pediatric Vaccines

Booster Shots
COVID-19 Globally

264.2 million cases
5.3 million deaths

Sources: NPR.org; Worldometer. Data as of 12/2/2021.
Daily New COVID-19 Cases Reported in the United States

- Early Spring
- Early Summer
- Late Fall

Source: Worldometer
- Epidemiology
- Variants
- Therapeutics
- Pediatric Vaccines
- Booster Shots
<table>
<thead>
<tr>
<th>WHO name</th>
<th>PANGO lineage*</th>
<th>Earliest documented samples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha</td>
<td>B.1.1.7</td>
<td>9/2020</td>
</tr>
<tr>
<td>Beta</td>
<td>B.1.351</td>
<td>5/2020</td>
</tr>
<tr>
<td>Gamma</td>
<td>P.1</td>
<td>11/2020</td>
</tr>
<tr>
<td>Delta</td>
<td>B.1.617.2</td>
<td>10/2020</td>
</tr>
<tr>
<td>Omicron</td>
<td>B.1.1.529</td>
<td>11/2021</td>
</tr>
</tbody>
</table>

*VOCs also include descendent lineages

Source: WHO
SARS-CoV-2 B.1.1.529 (Omicron) Variant

- Novel variant first reported in Botswana (11/11) and South Africa (11/14)
- Larger number of mutations (~50) than previous variants, some anticipated to impact transmissibility and antibody binding
- Variant cases rapidly increased in Gauteng province, South Africa, and present in all other S.A. provinces
- Confirmed cases (371) now reported from 24 countries (1 in United States)
- Called ‘Omicron’ by WHO and named the fifth SARS-CoV-2 variant of concern on 11/26/2021
Potential Properties of Omicron*

- **Transmission**
  - May have increased transmission compared to the original pandemic virus
  - Difficult to infer if more transmissible than Delta

- **Vaccine effectiveness**
  - Significant reductions in neutralizing titer possible
  - As with other variants, partial immune escape may occur, but vaccines likely will still protect against severe disease

- **Disease severity**
  - Severity estimates are difficult given small number of cases
  - Preliminary information from South Africa suggests no unusual symptoms associated with variant

*Based on Data for Other Variants with Similar Mutations*
First Confirmed Case of Omicron Variant Detected in the United States
Epidemiology

Variants

Therapeutics

Pediatric Vaccines

Booster Shots
Molnupiravir: Clinical Data Released Nov. 26, 2021 by Merck and Ridgeback Biotherapeutics

- Placebo-controlled trial; n = 1,433
- Endpoint: prevention of hospitalization or death
- 30% decrease in hospitalization/death in treatment arm; 9 deaths in placebo arm, 1 death in treatment arm
- FDA Advisory committee voted to approve drug for use in high-risk patients Nov 30, 2021
Paxlovid (Protease Inhibitor + Ritonavir): Clinical Data Announced Nov. 5, 2021 by Pfizer

- Placebo-controlled phase 2/3 trial of ~3,000 people; DSMB stopped study early at scheduled interim analysis of 1,219 people.

- Subjects with a laboratory-confirmed diagnosis of SARS-CoV-2 infection with mild-to-moderate symptoms and at least one characteristic/medical condition associated with an increased risk of developing severe illness from COVID-19.

- Patients randomized (1:1) to receive Paxlovid or placebo orally every 12 hours for five days.

- 89% reduction in hospitalization or death compared to placebo; 10 deaths in placebo arm, no deaths in treatment arm.

- Adverse events similar in placebo and treatment arms.
Epidemiology

Variants

Therapeutics

Pediatric Vaccines

Booster Shots
CDC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years

Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation that children 5 to 11 years old be vaccinated against COVID-19 with the Pfizer-BioNTech pediatric vaccine.
- Epidemiology
- Variants
- Therapeutics
- Pediatric Vaccines
- Booster Shots
Waning Immunity after COVID-19 Vaccination Among U.S. Veterans, 2021

Waning immunity against infection

Vaccine effectiveness (VE) against SARS-CoV-2 infection declined from 87.9% to 48.1% from Feb. to Oct., 2021

From July to October 2021 (Delta predominant period), VE against COVID-19 death:

- age <65 years: 73.0% for Janssen, 81.5% for Moderna, 84.3% for Pfizer-BioNTech
- age ≥65 years: 52.2% for Janssen, 75.5% for Moderna, 70.1% for Pfizer-BioNTech

Israel: Cumulative Incidence Curves Comparing COVID-19-Related Hospital Admissions, Severe Disease and Death in People Who Received 2 Versus 3 Doses of BNT162b2 Vaccine

Study C4591031: Efficacy & Safety of BNT162b2 Booster

- ~10,000 participants ≥16 years of age in Brazil, South Africa and United States
- In 2-month interim analysis, efficacy against symptomatic COVID-19 in the boosted group compared to the unboosted group was 95.6%
- Efficacy was consistent irrespective of age, sex, race, ethnicity, comorbid conditions
- Adverse events were consistent with those seen in previous studies

Source: JL Perez (Pfizer), ACIP meeting, 11/19/2021.
Study C4591031: Cumulative Incidence Curve for First COVID-19 Occurrence After Booster Vaccination

Source: JL Perez (Pfizer), ACIP meeting, 11/19/2021.
Every Adult Should Get a Booster Shot

CDC Expands COVID-19 Booster Recommendations
SARS-CoV-2 in 2022: What the Future Holds